Log in

Relevant bibliographies by topics / Heterologous prime-boost

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers

Academic literature on the topic 'Heterologous prime-boost'

Author: Grafiati

Published: 14 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Heterologous prime-boost.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Heterologous prime-boost"

1

Lu, Shan. "Heterologous prime–boost vaccination." Current Opinion in Immunology 21, no. 3 (2009): 346–51. http://dx.doi.org/10.1016/j.coi.2009.05.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pan, Chien-Hsiung, Hui-mei Hu, Yu-Ju Hsiao, and Sze-Hsien Wu. "Heterologous prime-boost vaccination with DNA vaccine and recombinant subunit containing four serotypes of dengue virus envelope protein domain III elicits neutralizing antibodies and specific T-cell responses (P4327)." Journal of Immunology 190, no. 1_Supplement (2013): 123.27. http://dx.doi.org/10.4049/jimmunol.190.supp.123.27.

Full text

Abstract:

Abstract Dengue is still an important public health problem and no dengue vaccine is available now. In this study, we characterized prime-boost vaccine regimens using heterologous and homologous dengue DNA vaccine and recombinant subunit vaccine consisted of envelope (E) protein domain III (ED III) from four serotypes of dengue virus (DENV). A broader and balanced IFN-gamma and IL-4 responses was observed in DNA-prime and subunit-boost immunized mice, compared to a narrower but strong IFN-gamma production after homologous DNA vaccination and an IL-4 only response in homologous subunit vaccine

APA, Harvard, Vancouver, ISO, and other styles

3

Tang, Xian, and Zhiwei Chen. "Heterologous immunization induces potent anti-SIV immunity with qualitative and quantitative improvements (53.22)." Journal of Immunology 186, no. 1_Supplement (2011): 53.22. http://dx.doi.org/10.4049/jimmunol.186.supp.53.22.

Full text

Abstract:

Abstract Background: The live replication-competent modified vaccinia virus Tiantan (MVTT) is an attractive vaccine vector. In this study, we constructed a recombinant MVTT expressing SIV Gag-Pol and Env (MVTT-SIV) and compared its efficacy for inducing antigen-specific immunity when administrated in different routes with or without rAd5-based vaccine encoding the same antigens (rAd5-SIV). Methods: MVTT-SIV was tested for its immunogenicity in mice administered homologously by a prime-boost strategy or heterologously in combination with rAd5-SIV. The prime routes included intranasal (IN), subl

APA, Harvard, Vancouver, ISO, and other styles

4

ZHANG, G., V. T. T. HUONG, B. BATTUR, et al. "A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity againstToxoplasma gondiiinfection in mice." Parasitology 134, no. 10 (2007): 1339–46. http://dx.doi.org/10.1017/s0031182007002892.

Full text

Abstract:

SUMMARYThe dense granule antigen 4 (GRA4) is known as an immundominant antigen ofToxoplasma gondiiand, therefore, is considered as a vaccine candidate. For further evaluation of its vaccine effect, a recombinant plasmid and vaccinia virus, both expressing GRA4, were constructed, and a heterologous prime-boost vaccination regime was performed in a mouse model. The mice immunized with the heterologous prime-boost vaccination regime showed a high level of specific antibody response against GRA4 and a significantly high level of gamma interferon (IFN-γ) production and survived completely against a

APA, Harvard, Vancouver, ISO, and other styles

5

Garg, Ishan, Abu Baker Sheikh, Suman Pal, and Rahul Shekhar. "Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review." Infectious Disease Reports 14, no. 4 (2022): 537–46. http://dx.doi.org/10.3390/idr14040057.

Full text

Abstract:

Various safe and effective COVID-19 vaccines utilizing different platforms (mRNA, adenovirus vector, inactivated virus-based) are available against SARS-CoV-2 infection. A prime-boost regimen (administration of two doses) is recommended to induce an adequate and sustained immune response. Most of these vaccines follow a homologous regimen (the same type of vaccine as priming and booster doses). However, there is a growing interest in a heterologous prime-boost vaccination regimen to potentially help address concerns posed by fluctuating vaccine supplies, serious adverse effects (anaphylaxis an

APA, Harvard, Vancouver, ISO, and other styles

6

Folegatti, Pedro M., Amy Flaxman, Daniel Jenkin, et al. "Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies." Vaccines 9, no. 3 (2021): 262. http://dx.doi.org/10.3390/vaccines9030262.

Full text

Abstract:

Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacterium avium subspecies paratuberculosis antigens as a single dose or as a booster vaccine following a simian adenovirus (ChAdOx2) prime. We demonstrate that a heterologous prime-boost schedule is well tolerated and induced T-cell immune responses.

APA, Harvard, Vancouver, ISO, and other styles

7

Carlétti, Dyego, Denise Morais da Fonseca, Ana Flávia Gembre, et al. "A Single Dose of a DNA Vaccine Encoding Apa Coencapsulated with 6,6′-Trehalose Dimycolate in Microspheres Confers Long-Term Protection against Tuberculosis in Mycobacterium bovis BCG-Primed Mice." Clinical and Vaccine Immunology 20, no. 8 (2013): 1162–69. http://dx.doi.org/10.1128/cvi.00148-13.

Full text

Abstract:

ABSTRACTMycobacterium bovisBCG prime DNA (Mycobacterium tuberculosisgenes)-booster vaccinations have been shown to induce greater protection against tuberculosis (TB) than BCG alone. This heterologous prime-boost strategy is perhaps the most realistic vaccination for the future of TB infection control, especially in countries where TB is endemic. Moreover, a prime-boost regimen using biodegradable microspheres seems to be a promising immunization to stimulate a long-lasting immune response. The alanine proline antigen (Apa) is a highly immunogenic glycoprotein secreted byM. tuberculosis. This

APA, Harvard, Vancouver, ISO, and other styles

8

Dai, Ming-Shen, Ren-In You, Yu-Feng Hsieh, et al. "Early Treg suppression by a Listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer (165.49)." Journal of Immunology 186, no. 1_Supplement (2011): 165.49. http://dx.doi.org/10.4049/jimmunol.186.supp.165.49.

Full text

Abstract:

Abstract [Background] Earlier studies have shown that higher CD8+ T-cell response and better tumor protection can be achieved by heterologous prime-boost vaccination in mice. We previously demonstrated that a Listeriolysin-O (LLO)-expressing E. coli vaccine can enhanced CD8-cytotoxic T cell (CTL) responses by mitigating regulatory T cells (Treg)-mediated suppression. We herein employed this Treg-inhibiting vaccine into the prime/boost immunization strategy. [Methods] Bacteria E. coli-LLO expressing Ovalbumin (OVA) and plasmid pcDNA—encoding OVA were used as specific antigen immunization. C57B6

APA, Harvard, Vancouver, ISO, and other styles

9

Santra, Sampa, Yue Sun, Jenny G. Parvani, et al. "Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors." Journal of Virology 81, no. 16 (2007): 8563–70. http://dx.doi.org/10.1128/jvi.00744-07.

Full text

Abstract:

ABSTRACT As the diversity of potential immunogens increases within certain classes of vectors, the possibility has arisen of employing heterologous prime/boost immunizations using diverse members of the same family of vectors. The present study was initiated to explore the use of divergent pox vectors in a prime/boost regimen to elicit high-frequency cellular immune responses to human immunodeficiency virus type 1 envelope and simian immunodeficiency virus gag in rhesus monkeys. We demonstrated that monkeys vaccinated with a recombinant modified vaccinia virus Ankara (rMVA) prime/recombinant f

APA, Harvard, Vancouver, ISO, and other styles

10

Kaku, Chengzi I., Elizabeth R. Champney, Johan Normark, et al. "Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination." Science 375, no. 6584 (2022): 1041–47. http://dx.doi.org/10.1126/science.abn2688.

Full text

Abstract:

Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy. We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)–specific serological and memory B cell (MBC) responses in individuals who received either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous messenger RNA (mRNA) booster immunization induced higher serum neutralizing antibody and MBC responses against SARS-CoV-2 variants of concern (VOCs) compared with that of homologous ChAdOx1 boosting. Spe

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Heterologous prime-boost"

1

Badamchi-Zadeh, Alexander. "Heterologous prime-boost vaccine regimens against Chlamydia trachomatis." Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/25021.

Full text

Abstract:

Chlamydia trachomatis is the most common bacterial sexually transmitted disease in man and despite decades of effort, there is still no protective vaccine. Left untreated, genital infection can lead to pelvic inflammatory disease, ectopic pregnancy, and infertility. However, infection-induced immunity in both animal models and humans indicates a strong role for CD4+ Th1-biased immune responses. Using a multi-component vaccine approach we assessed the immunogenicity and protective efficacy of novel plasmid DNA, Adenovirus 5 (HuAd5) and modified vaccinia Ankara (MVA) vectors each containing a ma

APA, Harvard, Vancouver, ISO, and other styles

2

Lange, Uta Gisela. "Heterologous prime-boost strategies in the development of novel vaccines against leishmaniasis." Thesis, University of Cambridge, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.619876.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Philosof, Bar. "A bacterium from the human microbiota as a vaccine vector. Efficient priming of the murine immune system by vaginal delivery of recombinant Streptococcus gordonii." Doctoral thesis, Università di Siena, 2022. http://hdl.handle.net/11365/1216735.

Full text

Abstract:

The ability to prime the immune system against an antigen, and to rapidly recall this response upon antigen reencounter is a fundamental characteristic of the adaptive immune response. The association of an antigen recognized by the immune system in a certain tissue, with the same antigen encountered at a later timepoint in a different tissue, is of primary importance to obtain a systemic and effective immune response and is the foundation behind the utilization of vaccines. The study of vaccine delivery platforms that may activate the immune system in such a manner is therefore of primary imp

APA, Harvard, Vancouver, ISO, and other styles

4

Searle, Benjamin James. "Characterisation of heterologous prime-boost vaccination strategies : an investigation into the nature and delivery of vaccines and the subsequent generation of immune responses." Thesis, University of Glasgow, 2004. http://theses.gla.ac.uk/2779/.

Full text

Abstract:

This thesis describes work undertaken to consider how strategies of vaccination can be manipulated to generate specific types and magnitude of immune response to prevent infection or treat established infection. The vaccination strategies employed were based on the initial delivery of DNA vaccine through intramuscular injection or ballistic delivery using a gene gun, followed by heterologous boosts, based on the same antigen delivered using an alternative route. These boost strategies included a) intramuscular delivery of purified recombinant HBcAg, b) mucosal delivery of HBcAg expressed by an

APA, Harvard, Vancouver, ISO, and other styles

5

"Plague vaccine: Homologous and heterologous prime-boost strategies using recombinant Yersinia pestis proteins." Tulane University, 2005.

Find full text

Abstract:

Yersinia pestis has been identified as a potential agent of biological warfare or bioterrorism and presents a particular challenge to vaccine developers because of the severity and potential transmissibility of the pneumonic form of the disease in humans. A Y. pestis-derived fusion protein (F1-V) has shown great promise as a protective antigen in murine studies. Here, initial studies were done to examine the ability of different prime-boost regimens, including parenteral, mucosal, and transcutaneous delivery, to induce a specific immune response of high titer and long duration. Next, we examin

APA, Harvard, Vancouver, ISO, and other styles

6

Huang, Yu-Hsuan, and 黃于璇. "Enhanced immune responses elicited by heterologous prime-boost vaccination using DNA/adenoviral vectors and protein of H5N1 hemagglutinin." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/92699131900412448191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

"Searching for an HIV Vaccine: A Heterologous Prime-boost System using Replicating Vaccinia Virus and Plant-produced Virus-like Particles." Doctoral diss., 2016. http://hdl.handle.net/2286/R.I.40210.

Full text

Abstract:

abstract: The HIV-1 pandemic continues to cause millions of new infections and AIDS-related deaths each year, and a majority of these occur in regions of the world with limited access to antiretroviral therapy. Therefore, an HIV-1 vaccine is still desperately needed. The most successful HIV-1 clinical trial to date used a non-replicating canarypox viral vector and protein boosting, yet its modest efficacy left room for improvement. Efforts to derive novel vectors which can be both safe and immunogenic, have spawned a new era of live, viral vectors. One such vaccinia virus vector, NYVAC-KC, was

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Heterologous prime-boost"

1

Palmowski, Michael J., and Caroline Smith. "Heterologous Prime-Boost Vaccination in Tumor Immunotherapy." In Handbook of Cancer Vaccines. Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-680-5_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jackson, Ronald J., David B. Boyle, and Charani Ranasinghe. "Progresses in DNA-Based Heterologous Prime-Boost Immunization Strategies." In Methods in Molecular Biology. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0410-5_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

McShane, Helen, Adrian Hill, and Andrew McMichael. "Overview of Heterologous Prime-Boost Immunization Strategies." In New Generation Vaccines, Fourth Edition. CRC Press, 2009. http://dx.doi.org/10.3109/9781420060744-39.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Shnawa, Ibrahim M. S. "Heterologous Prime-boost as COVID-19 Vaccine Strategies: Towards a Nationwide Implementation." In Challenges and Advances in Pharmaceutical Research Vol. 4. Book Publisher International (a part of SCIENCEDOMAIN International), 2022. http://dx.doi.org/10.9734/bpi/capr/v4/16535d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Srivastava, Indresh, Jeffrey Ulmer, Margaret Liu, Adrian Hill, Joerg Schneider, and Andrew McMichael. "DNA-Modified Virus Ankara and Other Heterologous Prime-Boost Immunization Strategies for Effector T Cell Induction." In New Generation Vaccines, Fourth Edition. Informa Healthcare, 2004. http://dx.doi.org/10.1201/9781439834404.ch31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

"DNA-Modified Virus Ankara and Other Heterologus Prime-Boost Immunization Strategies for Effector T Cell Induction." In New Generation Vaccines. CRC Press, 2004. http://dx.doi.org/10.1201/9781439834404-38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Heterologous prime-boost"

1

Azevedo, Patrick, Natália Souza, Lídia Faustino, Beatriz Santos, Alexandre Machado, and Ricardo Gazzinelli. "Evaluation of humoral and cellular immune response after heterologous prime-boost immunization against SARS-CoV-2." In International Symposium on Immunobiological. Instituto de Tecnologia em Imunobiológicos, 2021. http://dx.doi.org/10.35259/isi.2021_46710.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Blair, Wade, Gijsbert Grotenbreg, Ciaran Scallan, et al. "Abstract 724: A novel heterologous prime boost vaccine system drives tumor specific and potent CD8 T cell responses for cancer immunotherapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-724.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

KIM, SUNGBAE, KyungHae Jung, JinHee Ahn, and Jeongeun Kim. "Abstract CT414: Efficient induction of cellular and humoral immune responses by heterologous prime-boost therapeutic vaccination, involving plasmid DNA and adenoviral vector, in subjects with HER2-expressing breast cancer: Results from a phase Ib study." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-ct414.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!